Form 8-K - Current report:
SEC Accession No. 0001558370-20-006724
Filing Date
2020-05-15
Accepted
2020-05-15 16:04:44
Documents
17
Period of Report
2020-05-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K edit-20200515x8k.htm   iXBRL 8-K 38456
2 EX-1.1 edit-20200515xex1d1.htm EX-1.1 392266
3 EX-5.1 edit-20200515xex5d1.htm EX-5.1 18964
4 GRAPHIC edit-20200515xex5d1g001.jpg GRAPHIC 8096
5 GRAPHIC edit-20200515xex5d1g002.gif GRAPHIC 1668
6 GRAPHIC edit-20200515xex5d1g003.gif GRAPHIC 996
  Complete submission text file 0001558370-20-006724.txt   644847

Data Files

Seq Description Document Type Size
7 EX-101.SCH edit-20200515.xsd EX-101.SCH 3052
8 EX-101.LAB edit-20200515_lab.xml EX-101.LAB 15384
9 EX-101.PRE edit-20200515_pre.xml EX-101.PRE 9975
11 EXTRACTED XBRL INSTANCE DOCUMENT edit-20200515x8k_htm.xml XML 4678
Mailing Address 11 HURLEY ST. CAMBRIDGE MA 02141
Business Address 11 HURLEY ST. CAMBRIDGE MA 02141 617-401-9000
Editas Medicine, Inc. (Filer) CIK: 0001650664 (see all company filings)

EIN.: 464097528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37687 | Film No.: 20884960
SIC: 2836 Biological Products, (No Diagnostic Substances)